We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zimmer Biomet Buys Clinical Graphics, Boosts Hip Business
Read MoreHide Full Article
In line with its strategy to grow through inorganic means, Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has completed yet another mega acquisition. This musculoskeletal major has now announced the buyout of Clinical Graphics, B.V., an imaging company that works on 3D range-of-motion simulation technology needed for common hip conditions.
According to Zimmer Biomet, this acquisition is a strategic fit as post integration, the 3D imaging platform of Clinical Graphics should expand the company’s hip preservation portfolio. However, the company did not disclose the financial terms of the agreement.
Zimmer Biomet is highly optimistic about this inclusion. According to the company, being the next generation of treating joint pain, 3D imaging has become an extremely important treatment option in the musculoskeletal market. Clinical Graphics’ 3D interactive range-of-motion simulation particularly addresses common hip conditions like femoroacetabular impingement and dysplasia.
Zimmer Biomet has forged ahead with its expansion plans through acquisitions in the recent past. Last month, the company announced the takeover of CD Diagnostics, an immunoassays and biomarker testing developer, for an undisclosed term. Earlier this year, it had acquired LDR Holding for $1 billion.
According to the company, the buyout of this French spine device maker will not only bolster its presence in the $10 billion global spine market by significantly expanding its portfolio of innovative solutions, but will also provide it with a leading position in the fast growing cervical disc replacement (CDR) and Minimally Invasive Solutions (MIS) segments.
Also, worth mentioning is the grand $13.35 billion acquisition of Biomet. Post closing, the consolidated company Zimmer Biomet has emerged as a leading innovator in the $45 billion musculoskeletal industry, ramping up the merged entity's position in the competitive niche. Net synergies from the merger are currently anticipated to exceed $350 million in pre-tax by the end of the third year, post-transaction.
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zimmer Biomet Buys Clinical Graphics, Boosts Hip Business
In line with its strategy to grow through inorganic means, Zimmer Biomet Holdings, Inc. (ZBH - Free Report) has completed yet another mega acquisition. This musculoskeletal major has now announced the buyout of Clinical Graphics, B.V., an imaging company that works on 3D range-of-motion simulation technology needed for common hip conditions.
According to Zimmer Biomet, this acquisition is a strategic fit as post integration, the 3D imaging platform of Clinical Graphics should expand the company’s hip preservation portfolio. However, the company did not disclose the financial terms of the agreement.
Zimmer Biomet is highly optimistic about this inclusion. According to the company, being the next generation of treating joint pain, 3D imaging has become an extremely important treatment option in the musculoskeletal market. Clinical Graphics’ 3D interactive range-of-motion simulation particularly addresses common hip conditions like femoroacetabular impingement and dysplasia.
Price
Price | Quote
Zimmer Biomet has forged ahead with its expansion plans through acquisitions in the recent past. Last month, the company announced the takeover of CD Diagnostics, an immunoassays and biomarker testing developer, for an undisclosed term. Earlier this year, it had acquired LDR Holding for $1 billion.
According to the company, the buyout of this French spine device maker will not only bolster its presence in the $10 billion global spine market by significantly expanding its portfolio of innovative solutions, but will also provide it with a leading position in the fast growing cervical disc replacement (CDR) and Minimally Invasive Solutions (MIS) segments.
Also, worth mentioning is the grand $13.35 billion acquisition of Biomet. Post closing, the consolidated company Zimmer Biomet has emerged as a leading innovator in the $45 billion musculoskeletal industry, ramping up the merged entity's position in the competitive niche. Net synergies from the merger are currently anticipated to exceed $350 million in pre-tax by the end of the third year, post-transaction.
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some of the better-ranked medical products stocks are NuVasive, Inc. , Quidel Corp. (QDEL - Free Report) and GW Pharmaceuticals plc . All the three stocks sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>